ABVC BioPharma, Inc.
ABVC
$2.41
-$0.12-4.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.47% | 240.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.50% | 231.17% | |||
| Operating Income | 49.19% | -231.17% | |||
| Income Before Tax | 44.27% | -144.57% | |||
| Income Tax Expenses | -97.88% | -- | |||
| Earnings from Continuing Operations | 44.81% | -147.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -45.91% | -25.76% | |||
| Net Income | 44.77% | -168.02% | |||
| EBIT | 49.19% | -231.17% | |||
| EBITDA | 49.29% | -233.57% | |||
| EPS Basic | 58.71% | -130.55% | |||
| Normalized Basic EPS | 59.22% | -152.46% | |||
| EPS Diluted | 58.71% | -130.55% | |||
| Normalized Diluted EPS | 59.22% | -152.46% | |||
| Average Basic Shares Outstanding | 33.76% | 16.16% | |||
| Average Diluted Shares Outstanding | 33.76% | 16.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||